Advanced Search

Decision Of October 16, 2013, Bringing Delegations Of Signature To The National Agency For Safety Of The Drug And Health Products

Original Language Title: Décision du 16 octobre 2013 portant délégations de signature à l'Agence nationale de sécurité du médicament et des produits de santé

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.

Information on this text




JORF no.0247 of 23 October 2013
text No. 9



Decision of October 16, 2013 to the National Agency for the Safety of Medicine and Health Products

NOR: AFSM1300195S ELI: https://www.legifrance.gouv.fr/eli/decision/2013/10/16/AFSM1300195S/jo/texte


Director General of the National Drug and Health Products Safety Agency,
Vu le Public Health Codearticles L. 5311-1 et seq. and R. 5322-14;
Vu la Act No. 2011-2012 of 29 December 2011 on strengthening the health safety of the drug and health products;
Vu le Decree No. 2012-597 of 27 April 2012 the National Drug Safety Agency and Health Products;
Having regard to the decree of May 1, 2012 appointing the Director General of the National Agency for the Safety of Medicine and Health Products - Mr. Maraninchi (Dominique);
Having regard to Decision No. 2012-237 of 24 September 2012, as amended, organizing the National Drug Safety Agency and Health Products;
In light of Decision No. 2012-238 of 24 September 2012 amended appointing the National Drug and Health Products Safety Agency;
In light of Decision No. 2012-239 of 24 September 2012 amended by delegations of signature to the National Drug and Health Products Safety Agency,
Decides:

Article 1


Decision No. 2012-239 dated September 24, 2012 with delegation of signature to the National Agency for the Safety of Drugs and Health Products referred to above is amended as follows:
I. ∙ Article 3 II is read as follows:
“II. ― Permanent Delegation is given to Ms. DOUCET (Dominique), Head of the Documentation Pole, and to Ms. MOUAS (Houria), Head of the Professional and Public Information Hub, to the effect of signing, on behalf of the Director General of the National Agency for the Safety of Medicine and Health Products, all decisions within the scope of their respective poles. »
II. — Article 9 II is read as follows:
“II. ― Permanent Delegation is given to Ms. LEVY (Cécile), Head of the Interim Flow Management Pole, and to Ms. LEFEBVRE-RAISIN (Laurence), Head of the Reference Management Pole, to sign, on behalf of the Director General of the National Drug Safety Agency and Health Products, all decisions within the scope of the responsibilities of their respective poles. »
III. ― Article 12 III is read as follows:
"III. ― Permanent delegation is given to Mr. RIBES (Olivier), Head of the Biologic Inspection Unit, Mr. VIORNERY (Lionel), Head of the Pharmaceutical Inspection Unit and Counter Fraud Control Unit 1, and to Ms. RIBEIRO (Virginie), Head of the Pharmaceutical Inspection Unit and Control of Fraud Unit 2, to Mr. RENAUD (Guillaume), Head of the Primary Material Inspection Unit »
IV. ― Article 16 I reads as follows:
"I. ― Permanent Delegation is given to Mr. EMMERICH (Joseph), Director, and to Ms. DRUET (Céline), Deputy Director, to the effect of signing, on behalf of the Director General of the National Agency for the Safety of Medicine and Health Products, all decisions within the limits of the responsibilities of the management of medications in cardiology, endocrinology, gynaecology, urology. »

Article 2


This decision will be published in the Official Journal of the French Republic.


Done on 16 October 2013.


D. Maraninchi


Download the document in RTF (weight < 1MB) Extrait du Journal officiel électronique authentifié (format: pdf, weight : 0.16 MB) Download the document in RDF (format: rdf, weight < 1 MB)